摘要
二肽基肽酶(DPP-Ⅳ)抑制剂是治疗Ⅱ型糖尿病的新药,因其无低血糖、体重增加以及胃肠道相关问题而备受青睐。本文综述DPP-Ⅳ抑制剂上市品种的市场表现及后续品种的开发。
Dipeptidyl peptidase IV（DPP-IV） inhibitor has been used as a new therapeutic option for the treatment of type II diabetes. Its rapid rise in popularity is due to the favorable profile such as no hypoglycemia, no weight gain and no gastrointestinal problems. This paper reviews the market performance and the development of DPP-IV inhibitors.
出处
《世界临床药物》
CAS
2011年第12期754-757,共4页
World Clinical Drug
关键词
DPP-Ⅳ抑制剂
降糖药
医药市场
DPP-IV inhibitor
anti-diabetic drug
pharmaceutical market
